Scholars Central

Conference abstractPublished 26 Oct 2015

Issues in the Clinical Development of the first Wave of Biosimilars

Authors: Nigel J Rulewski

Quintiles, Inc., USA

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Biosimilars in the US are still in their infancy with only one product approved for the US market to date. However the first wave of Biosimilar products, EPO, Filgrastim, Anti TNFs and several oncology products are now well underway. The issues faced in the development of these products have evolved over time and now provide a firm basis for the next generation of biosimilar products. The issues surrounding the choice of indication in which to demonstrate biosimilarity, the basis of extrapolation and the need for transition data have all now been established. Interchangeability, a situation unique to the US approval systems still remains to be clarified, although the FDA’s likely requirements are becoming clearer. Levels of interest expressed by clinical investigators has increased significantly as the financial consequences of biosimilars become better understood. The issues encountered in the clinical development of this first wave of biosimilars and the implications of those lessons learnt for the next wave of products will be discussed.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Nigel J Rulewski”